Blood Biomarkers Predict Response in Autoimmune Diabetes Study
Researchers at Bar-Ilan University identified two pre-treatment RNA markers that predicted which mice entered remission on a three-drug regimen.
Researchers Identify Blood Biomarkers for Autoimmune Diabetes Treatment
Pre-treatment blood biomarkers accurately predicted which mice would respond to an experimental drug combination for latent autoimmune diabetes in adults (LADA), according to an animal study published in MedComm.
Investigators at Bar-Ilan University tested a three-drug regimen pairing gamma-aminobutyric acid (GABA), sitagliptin, and omeprazole in a mouse model of the disease. Approximately 30% of the treated animals achieved complete remission, maintaining normal blood sugar levels and remaining diabetes-free for weeks after therapy ended.
The remaining mice showed little or no improvement, highlighting the wide variability often observed in autoimmune therapies.
Two Cell-Free RNA Markers Distinguished Responders
Two circulating cell-free RNA (cfRNA) biomarkers, Adgrb1 and Chd5, separated responders from nonresponders prior to receiving any medication.
A team led by Dr. Shira Perez at the Azrieli Faculty of Medicine genomic center measured these circulating markers in baseline blood samples. The presence of these specific RNA profiles accurately signaled which animals would clear the disease on the regimen.
Beta Cell Regeneration Explains Remission in Responding Mice
Tissue analysis showed that the combination therapy spurred pancreatic regeneration rather than merely preserving remaining cells.
Examination of the pancreases in cured mice revealed that the recovery occurred primarily through the replication of existing insulin-producing beta cells. The experimental therapy appeared to operate through two distinct pathways simultaneously.
The regimen lowered immune activity against the pancreas, which allowed newly divided beta cells to survive and restore endogenous insulin production.
Why Distinguishing LADA Matters for Metabolic Care
Latent autoimmune diabetes in adults accounts for an estimated 2% to 12% of all adult diabetes cases.
Because individuals with LADA continue to produce endogenous insulin in the early stages, the condition is frequently misdiagnosed as type 2 diabetes. As a consequence, many patients initially receive standard metabolic therapies that fail to address the underlying autoimmune destruction of pancreatic beta cells.
If future trials validate these circulating biomarkers in human subjects, clinicians could use baseline blood tests to select candidates for targeted immune-modulating regimens.
Current Limitations of the Preclinical Findings
These results are currently limited to a mouse model and have not yet been evaluated in human clinical trials.
The combination of GABA, sitagliptin, and omeprazole remains strictly experimental for autoimmune diabetes, and human patients should not attempt self-directed regimens using these agents.
Substantial additional research is required to confirm whether the Adgrb1 and Chd5 markers replicate in clinical cohorts before any diagnostic or therapeutic protocol can be established.
Related Articles
Smart Floss Prototype Measures Blood Sugar and Gum Inflammation
A prototype dental floss device developed by HKUST researchers samples gingival fluid to measure...
Read article TestingNight-Shift Work Linked to Differences in Heart Structure and Blood Markers
An observational study of 42,671 adults links frequent night-shift work to thicker heart walls,...
Read article TestingBlood Test for P-Tau217 Estimates Ten-Year Cognitive Impairment Risk
A Mayo Clinic study in JAMA Neurology shows blood p-tau217 combined with age and genetics can...
Read article TestingBiomarker for GHB Detection Extends Forensic Testing Window
A University of Zurich study in Drug Testing and Analysis shows the biomarker GHB-pentose...
Read articleWant to know what your markers actually mean?
Opt Health publishes a guide to the 55+ biomarkers they test and what each one tells you — the same panel they run before building a treatment plan.
Read Opt Health's biomarker guide →Topic updates
Get the weekly lab marker roundup
Blood test interpretation, optimal ranges, fasting insulin, A1C, thyroid panels, testosterone, cortisol, and nutrient markers.
Understand Your Health Better
Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results